Equels Thomas K 4

What Happened

• Thomas K. Equels, CEO and President of AIM ImmunoTech, reported derivative acquisitions on 2026-03-06: 25 preferred/share-class units at $25,000 each (total value reported $625,000) and 50,000 warrants acquired at $0. Both items were reported as "Other acquisition or disposition (J)" on a Form 4 and were issued as part of a rights offering. These are acquisitions (insider received derivative securities rather than selling common stock).

Key Details

• Transaction date: 2026-03-06; Form 4 filed 2026-03-10 (filed within required reporting window).
• 25 preferred-class units acquired at $25,000.00 each; total reported value $625,000 (derivative instrument).
• 50,000 warrants acquired at $0.00 (derivative instrument; reported value $0).
• Conversion/exercise terms in filing:
  • Footnote F1: Each preferred share has a stated value and is convertible into 1,000 shares of common stock and was issued via subscription rights in the rights offering.
  • Footnote F2: Preferred shares are perpetual.
  • Footnote F3: Each warrant is exercisable for one share of common stock at $1.00 and was issued in the rights offering (exercising all 50,000 warrants would require $50,000 cash at $1.00 per share).
• Shares owned after the transaction: not specified in the Form 4 filing.

Context

• These were derivative securities received via a rights offering, not immediate purchases of common stock — converting preferred shares or exercising warrants would be separate actions and may require payment (warrants have a $1.00 exercise price). Derivative acquisitions can increase potential future common share exposure but are not identical to an open-market common-share buy.